Cartesian Therapeutics, a biopharmaceutical company that specializes in mRNA-engineered cell therapy, recently announced the start of a Phase 2a clinical trial of its mRNA chimeric antigen receptor (CAR) T-cell therapy, Descartes-11, in patients with newly diagnosed, high-risk multiple myeloma. DocWire News spoke with Murat Kalayoglu, MD, PhD, President and Chief Executive Officer at Cartesian Therapeutics, […]

Oliver hosts Erez Raphael, the CEO of the global digital therapeutics company DarioHealth (DRIO) to discuss recent 4Q earnings results and the firm’s outlook going forward.

Valo Therapeutics (Valo TX) has partnered with ImmunoScape to identify immunogenic peptides for pan-coronavirus vaccine development. The detected conserved peptide sequences will be applied to adenoviruses to address efficacy problems with existing vaccines against novel Covid-19 variants. Valo Therapeutics’ PeptiVAX platform offers a flexible and quick approach to address variants by coating the adenovirus with the associated clinical-grade target […]